Literature DB >> 1733439

Effects on tumour microcirculation in mice of misonidazole and tumour necrosis factor plus hyperthermia.

S Fujimoto1, K Kobayashi, M Takahashi, C Konno, M Kokubun, M Ohta, R D Shrestha, S Kiuchi.   

Abstract

We examined the effects of misonidazole (MISO) and recombinant human tumour necrosis factor (rh-TNF) on tumour blood flow in mice given hyperthermic treatments. MISO (500 mg kg-1) or rh-TNF (6 x 10(4) unit kg-1) was administered intraperitoneally (i.p.) prior to hyperthermia to nude mice bearing a xenoplanted human gastric cancer and tumour blood flow was measured by a hydrogen diffusion method based on polarographic determinations. MISO plus hyperthermia produced a temperature-dependent decrease in blood flow and, at 43.5 degrees C, the flow decreased to 15-30% of control and remained low for up to 24 h. Blood flow following rh-TNF plus hyperthermia was less than that at the same temperatures following MISO plus hyperthermia, and, at 43.5 degrees C, the flow decreased to 10-20% of control and remained low for up to 48 h. Tumour growth delay was closely related to the duration of the decrease in blood flow. Thus, the profound decrease in tumour blood flow following hyperthermia plus MISO or rh-TNF and the consequential tumour regression may well be of potential clinical significance.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1733439      PMCID: PMC1977348          DOI: 10.1038/bjc.1992.6

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  26 in total

1.  EQUATIONS FOR MEASURING BLOOD FLOW BY EXTERNAL MONITORING OF RADIOISOTOPES.

Authors:  K L ZIERLER
Journal:  Circ Res       Date:  1965-04       Impact factor: 17.367

2.  MEASUREMENT OF LOCAL BLOOD FLOW WITH HYDROGEN GAS.

Authors:  K AUKLAND; B F BOWER; R W BERLINER
Journal:  Circ Res       Date:  1964-02       Impact factor: 17.367

3.  Proposal of standardized methods and reference for assaying recombinant human tumor necrosis factor.

Authors:  S Yamazaki; E Onishi; K Enami; K Natori; M Kohase; H Sakamoto; M Tanouchi; H Hayashi
Journal:  Jpn J Med Sci Biol       Date:  1986-06

4.  [A phase I study of recombinant human tumor necrosis factor (rHu-TNF: PT-050). The PT-050 Study Group].

Authors:  T Taguchi
Journal:  Gan To Kagaku Ryoho       Date:  1986-12

5.  Electron-affinic sensitization. VII. A correlation between structures, one-electron reduction potentials, and efficiencies of nitroimidazoles as hypoxic cell radiosensitizers.

Authors:  G E Adams; I R Flockhart; C E Smithen; I J Stratford; P Wardman; M E Watts
Journal:  Radiat Res       Date:  1976-07       Impact factor: 2.841

6.  Early metabolic response to tumor necrosis factor in mouse sarcoma: a phosphorus-31 nuclear magnetic resonance study.

Authors:  N Shine; M A Palladino; J S Patton; A Deisseroth; G S Karczmar; G B Matson; M W Weiner
Journal:  Cancer Res       Date:  1989-04-15       Impact factor: 12.701

7.  Augmented antitumour effects of combined treatment with hyperthermia and tumour necrosis factor on human gastric cancer xenotransplanted into nude mice.

Authors:  S Fujimoto; C Konno; K Kobayashi; M Kokubun; R D Shrestha; S Kiuchi; M Takahashi; M Ohta; K Okui
Journal:  Int J Hyperthermia       Date:  1991 May-Jun       Impact factor: 3.914

8.  Effect of hyperthermia on differential cytotoxicity of a hypoxic cell radiosensitizer, Ro-07-0582, on mammalian cells in vitro.

Authors:  I J Stratford; G E Adams
Journal:  Br J Cancer       Date:  1977-03       Impact factor: 7.640

9.  Misonidazole reduces blood flow in two experimental murine tumours.

Authors:  J C Murray; V S Randhawa
Journal:  Br J Cancer       Date:  1988-08       Impact factor: 7.640

10.  Interaction of hyperthermia and the hypoxic cell sensitizer Ro-07-0582 on the EMT6 mouse tumour.

Authors:  N M Bleehen; D J Honess; J E Morgan
Journal:  Br J Cancer       Date:  1977-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.